Lexicon Pharmaceuticals, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; it does not provide a standalone fourth-quarter financial summary. Lexicon is a clinical-stage biopharmaceutical company preparing to commercialize sotagliflozin, subject to FDA approval. Its common stock trades on Nasdaq under LXRX.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change or context |
|---|---|---|---|
| Total revenue | $0.139 million | $0.298 million | Down 53%; 2022 revenue was royalties and other revenue. One customer represented all 2022 revenue. |
| Research and development expense | $52.8 million | $55.0 million | Down 4%. |
| Selling, general and administrative expense | $48.1 million | $32.3 million | Up 49%, primarily reflecting commercialization preparation, higher personnel costs, and marketing and consulting fees. |
| Operating loss | $100.8 million | $87.1 million | Loss widened. |
| Net loss | $101.9 million | $87.8 million | Loss widened; basic and diluted loss per share was $0.62 versus $0.60. |
| Cash used in operating activities | $88.9 million | $87.0 million | Operating cash use remained high. |
| Cash, cash equivalents and short-term investments | $138.4 million | $86.7 million | At December 31; increased mainly following equity and debt financing. |
| Long-term debt, net of issuance costs | $48.6 million | None reported | Oxford term-loan borrowings; facility capacity is up to $150 million. |
2022 investing activities used $71.1 million, mainly reflecting net investment purchases; financing activities provided $142.2 million, including $94.2 million net proceeds from stock issuance and $48.9 million net Oxford loan proceeds. The filing reports no meaningful product-sales margin for 2022 because product revenue was zero. Lexicon reported an accumulated deficit of $1.6 billion and no income tax benefit, maintaining a valuation allowance against deferred tax assets.
Material changes versus the prior year
- R&D expense declined modestly, while SG&A increased substantially as Lexicon added personnel and commercial-preparation spending for sotagliflozin.
- Net loss grew by $14.2 million, alongside higher SG&A and interest expense; interest expense rose to $2.8 million from $0.8 million after Oxford financing.
- Liquidity increased, supported by a 39.1 million-share public offering and concurrent private placement to Invus affiliates, as well as new term debt. The share issuance increased common shares outstanding.
- The 2020 comparison is unusual: that year included $23.4 million in product revenue and a $132.6 million gain on the sale of XERMELO; neither was present in 2021 or 2022.
Outlook, milestones, and key risks
- Sotagliflozin for heart failure: The FDA was reviewing the NDA, with a PDUFA target action date of May 27, 2023. Management was preparing a potential U.S. launch, but approval, timing, labeling, reimbursement, uptake, and commercial success were uncertain.
- Sotagliflozin for type 1 diabetes: The FDA had issued a complete response letter. An administrative hearing process concerning potential grounds for denying the NDA was ongoing. The drug had been approved in the U.K. for a limited type 1 diabetes population, but Lexicon had not launched it commercially there.
- LX9211: Phase 2 diabetic peripheral neuropathic pain results met the primary endpoint at the low dose; the high dose narrowly missed statistical significance. The post-herpetic neuralgia trial missed its primary endpoint but showed evidence of effect. Lexicon said it lacked sufficient capital for a full Phase 3 program without a collaboration or other financing arrangement.
- Cash runway: Management expected existing capital and anticipated collaboration and other cash sources to fund currently planned operations for at least 12 months from the filing date. It warned that additional financing could be required and might not be available on acceptable terms.
- Debt and covenants: Oxford loans bear floating interest at 30-day U.S. dollar LIBOR plus 7.90%, subject to an 8.01% floor; the disclosed rate at year-end was 12.04%. The loans are secured by substantially all company assets and include covenants, including a post-approval sotagliflozin net-sales covenant. Lexicon reported covenant compliance at year-end.
- Other exposures: The company relies on third-party manufacturers and clinical vendors; faces regulatory, clinical, competition, pricing and reimbursement, intellectual-property, cybersecurity, and product-liability risks; and may need partners for development programs. Invus owned approximately 50.5% of outstanding common stock and had significant governance and consent rights.
- Contingencies and controls: Lexicon said ordinary-course legal matters were not expected to have a material adverse effect. The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective.
Important facts for investors to verify
- Subsequent FDA decisions and final labeling for sotagliflozin, plus any launch timing, sales, reimbursement, and post-approval obligations.
- Cash burn, available unrestricted liquidity, financing needs, and whether additional Oxford tranches are drawn or their conditions are met.
- Oxford loan interest, repayment schedule, collateral, covenants, and potential warrant-related dilution.
- Whether Lexicon secures a partner or funding for LX9211 Phase 3 development and the timing and design of any pivotal trials.
- Commercial-preparation spending and the extent to which future revenue remains dependent on a small number of customers or collaboration payments.
- Share-count changes and Invus’s continuing ownership, board designation, preemptive, and consent rights.